Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

Human Amniotic Epithelial Stem Cells is under clinical development by iCELL Biotechnology and currently in Phase I for Parkinson's Disease.

Gain will be working with local Parkinson’s disease (PD) advocacy groups to support enrollment and expects enrollment to complete in the spring of 2025 with data from the study expected mid-2025.

The participants were recruited based on specific criteria, including mild-to-moderate idiopathic Parkinson's disease and the ability to walk and stand unassisted. Baseline data were collected ...

The Company has received approval to begin enrollment of the Phase 1b clinical trial in AustraliaPhase 1b clinical trial will assess safety and ...

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggests that GT-02287 may have the potential to ...